Dear Dr. Guma:

Please refer to your supplemental biologics license application (sBLA), dated and received May 2, 2019, and your amendments, submitted under section 351(a) of the Public Health Service Act for Yervoy (ipilimumab) injection, for intravenous use.

We also refer to our approval letter dated June 29, 2020 which contained the following error:

- formatting errors and inconsistencies including outline numbering and text bolding in the Medication Guide.

This replacement approval letter incorporates the correction of the error. The effective approval date will remain June 29, 2020, the date of the original approval letter.

This Prior Approval supplemental biologics application provides for the following changes to the Prescribing Information (PI):

- Removal of the boxed warning for immune-mediated adverse reactions (IMARs);
- Updates to Section 2.5 Recommended Dose Modifications for Adverse Reactions;
- Major reorganization of Section 5 WARNINGS AND PRECAUTIONS to consolidate all the IMARs into one warning;
- Revisions to Efficacy tables in Section 14 CLINICAL STUDIES were consolidated to include all efficacy results for a specific study;
- Additional changes to language in the package insert for consistency and to update based on current regulations, recommendations and labeling practices.

**APPROVAL & LABELING**

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

U.S. Food and Drug Administration
Silver Spring, MD 20993
www.fda.gov
WAIVER OF HIGHLIGHTS ½ PAGE LENGTH REQUIREMENT FOR HIGHLIGHTS

Please note that we have previously granted a waiver of the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of Prescribing Information.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit, via the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 601.14(b)] in structured product labeling (SPL) format, as described at FDA.gov,¹ that is identical to the enclosed labeling (text for the Prescribing Information and Medication Guide) and include the labeling changes proposed in any pending “Changes Being Effected” (CBE) supplements.

Information on submitting SPL files using eLIST may be found in the guidance for industry SPL Standard for Content of Labeling Technical Qs and As.²

The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this BLA, including pending “Changes Being Effected” (CBE) supplements, for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 601.12(f)] in Microsoft Word format that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

¹ http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm
² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database https://www.fda.gov/RegulatoryInformation/Guidances/default.htm.
PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see the final guidance for industry Providing Regulatory Submissions in Electronic and Non-Electronic Format—Promotional Labeling and Advertising Materials for Human Prescription Drugs.3

As required under 21 CFR 601.12(f)(4), you must submit final promotional materials, and the Prescribing Information, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. Form FDA 2253 is available at FDA.gov.4 Information and Instructions for completing the form can be found at FDA.gov.5

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved BLA (in 21 CFR 600.80 and in 21 CFR 600.81).

If you have any questions, call Norma Griffin, Lead Regulatory Health Project Manager, at 301-796-4255.

Sincerely,

{See appended electronic signature page}

Jeffrey Summers, MD
Associate Director for Translational Sciences
Office of Oncologic Diseases
Center for Drug Evaluation and Research

ENCLOSURES:

- Content of Labeling
  - Prescribing Information
  - Medication Guide

---

3 For the most recent version of a guidance, check the FDA guidance web page at https://www.fda.gov/media/128163/download.
4 http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf
5 http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf
This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

JEFFERY L SUMMERS
06/29/2020 12:00:00 AM